Medical/Pharmaceuticals News & Press Release Distribution

Sirnaomics Receives IND Clearance from the "Taiwan Ministry of Health and Welfare" for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment

GAITHERSBURG, Md. and SUZHOU, China, July 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company has received regulatory clearance from t...

2022-07-26 16:58 2133

Intellect partners with Swiss Life Network to expand reach of comprehensive mental health care solutions in Asia

* Intellect joins hands with leading global employee benefits providers, Swiss Life Network * This partnership brings Intellect's comprehensive mental health solutions to workforces across APAC through Swiss Life Network's Clients and Network Partners SINGAPORE, July 26, 2022 /PRNewswire/ -- ...

2022-07-26 15:52 2624

Manulife enhances Cashless Day Surgery eService to diversify its comprehensive healthcare support

Expansion of specialist network, medical service providers, and categories of surgeries under eight major specialties offers customers more convenient quality health services HONG KONG, July 26, 2022 /PRNewswire/ -- Manulife Hong Kong today announced it has enhanced its Cashless Day Surgery eSer...

2022-07-26 12:33 3199

Otsuka Pharmaceuticals Implements Antibody Discovery, and Cell & Gene Therapy Research & Development by Utilizing the Berkeley Lights Beacon(R) Platform

EMERYVILLE, Calif., July 26, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced Otsuka Pharmaceuticals, a leading pharmaceutical company, has implemented the use of the Berkeley Lights Beacon® system for antibody discovery, as well as cell ...

2022-07-26 11:51 1837

Otsuka Pharmaceuticals Implements Antibody Discovery, and Cell & Gene Therapy Research & Development by Utilizing the Berkeley Lights Beacon® Platform

EMERYVILLE, Calif., July 26, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced Otsuka Pharmaceuticals, a leading pharmaceutical company, has implemented the use of the Berkeley Lights Beacon® system for antibody discovery, as well as cell ...

2022-07-26 11:43 1702

Molecular Diagnostics Developer INEX Innovate Announces Funding for New Research with The Chinese University of Hong Kong

Singapore-based diagnostics developer INEX Innovate brings The Chinese University of Hong Kong together to further research work on LEXI®, INEX's fetal cell based non-invasive pre-natal diagnostics technology. SINGAPORE, July 26, 2022 /PRNewswire/ -- Singapore-based diagnostics developer and med...

2022-07-26 08:30 2368

Molecular Diagnostics Developer INEX Innovate Announces Funding for New Research with The Chinese University of Hong Kong

CSafe Global Continues Investment in Cell and Gene Therapy Solutions with Addition of New Portfolio President

Amy DuRoss joins CSafe Global as President, Cell & Gene Therapy to drive innovation and solution development MONROE, Ohio, July 26, 2022 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled shipping solutions for the transport of life-enhancing pharmaceuticals, announced...

2022-07-26 03:35 2256

CSafe Global Continues Investment in Cell and Gene Therapy Solutions with Addition of New Portfolio President

Ascentage Pharma and Tanner Pharma Group Initiate a Global Innovative Named Patient Program

SUZHOU, China and ROCKVILLE, Md. and CHARLOTTE, N.C., July 25, 2022 /PRNewswire/ --Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, andTanner Ph...

2022-07-25 21:59 2102

Anti-PD-1 monoclonal antibody Puyouheng™ (HX-008, Pucotenlimab injection) Co-developed by LEPU BIOPHARMA and HANX BIOPHARMACEUTICALS was approved for marketing in China by NMPA

HANGZHOU, China, July 25, 2022 /PRNewswire/ -- Anti-PD-1 monoclonal antibody – PuyouhengTM (HX-008, pucotenlimab injection), was conditionally approved by the National Medical Products Administration (NMPA) for marketing inChina to treat patients with unresectable or metastatic microsatellite ins...

2022-07-25 18:47 1769

Fuzhou Rides on the Opportunity of "Digital China" to Make Its Name in the World

FUZHOU, China, July 25, 2022 /PRNewswire/ -- "Discover Fuzhou: The Digital China Summit", the themed promo film ofFuzhou City, Fujian Province, was shown on "China screen" at Times Square, New York on July 22. Riding on the opportunity of "Digital China",Fuzhou, a coastal city, is presenting its ...

2022-07-25 15:21 1905

Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform

* Rona to advance worldwide development of Sanofi siRNA portfolio targeting liver and other tissues * Rona licensed Sanofi's siRNA platform to enable discovery programs in expanded therapeutic areas including neuro and muscular diseases, for which Sanofi has an exclusive option to acquire neu...

2022-07-25 12:30 2213

Qiming's Portfolio Company InventisBio Lists on STAR Market

SHANGHAI, July 25, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price isCNY 18...

2022-07-25 11:55 3450

Qiming's Portfolio Company InventisBio Lists on STAR Market

SHANGHAI, July 24, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange.The issue price is CNY 18...

2022-07-25 11:55 2472

Handheld Technology from Baxter Makes Diabetic Retinopathy Screening Simple and Affordable for Primary Care Settings

Early Detection Can Prevent 95% of Vision Loss Cases SEOUL, South Korea, July 25, 2022 /PRNewswire/ -- Diabetic retinopathy is the leading cause of blindness among working-age adults globally.1 With early detection and treatment, as much as 95 percent of vision loss cases can be prevented.2 Com...

2022-07-25 08:30 2379

Handheld Technology from Baxter Makes Diabetic Retinopathy Screening Simple and Affordable for Primary Care Settings

US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL

* Investigational new drug (IND) approval received by QBiotics, to initiate a Phase II clinical trial investigating tigilanol tiglate in the treatment of patients with Soft Tissue Sarcoma (STS) * The open label trial will evaluate efficacy and dose ranging in patients with advanced or metasta...

2022-07-25 07:09 2135

4DMedical Lauds U.S. House of Representatives for Including Burn Pit Population Surveillance in FY 2023 Appropriations

Thousands of Impacted Veterans Will Benefit from Congressional Efforts LOS ANGELES, July 23, 2022 /PRNewswire/ -- 4DMedical, the leading developer of functional imaging software for respiratory illness, today praised the U.S. House of Representatives for including language calling on the Departme...

2022-07-23 00:59 4666

Merck Launches its Uptune Program in Asia for Collaborating with Startups

* Application period for the Merck Uptune program starts today * Topics vary from AI-enabled health and cell and gene therapy tools to innovative technologies and materials in semiconductor and smart manufacturing * Selected startups can receive funding of up to € 100,000 SINGAPORE, July 22,...

2022-07-22 14:37 2140

Merck Launches its Uptune Program in Asia for Collaborating with Startups

Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada

SUZHOU, China and ROCKVILLE, MD, July 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase Ib study of Ascentage Pharma's novel...

2022-07-22 07:59 2060

Congratulations! Kexing Biopharm (688136.SH) was awarded by the" Annual Top 20 Chinese Biopharmaceutical Entreprises"

SHENZHEN, China, July 21, 2022 /PRNewswire/ -- On 12 July 2022, Menet held the award ceremony of the "Annual Top 100 China's Pharmaceutical Entreprises in 2021", in which 5 sub-lists of the pharmaceutical industries had been announced. This event showcased the professionalism and influence of the...

2022-07-21 22:32 2422

Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

– Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication – – Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) inMay 2022 – NEWTON, Mass. and FLORENCE, Italy, July 21, 2022 /PRNewswire/ -- Karyopha...

2022-07-21 21:25 2587